Skip to main
BIOA

BIOA Stock Forecast & Price Target

BIOA Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 63%
Buy 25%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Bioage Labs is well-positioned in the biopharmaceutical industry, with a focus on targeting molecular causes of aging and partnerships with major pharmaceutical companies. Their strong financial position, promising lead asset and potential for expansion, along with expected positive results from ongoing clinical trials, make them a promising investment opportunity. However, potential competition from companies like AC Immune SA and financing risks should also be considered.

Bears say

Bioage Labs is facing potential delays in the development and commercialization of BGE-102, as well as challenges in finding success with their current research and development pipeline. Additionally, their partnership with Roche may not materialize as expected, leading to a lack of funding and resources for future projects. Furthermore, the company's relatively new presence in the biotechnology industry and lack of a proven track record may make it a risky investment option.

BIOA has been analyzed by 8 analysts, with a consensus rating of Buy. 63% of analysts recommend a Strong Buy, 25% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioAge Labs Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioAge Labs Inc (BIOA) Forecast

Analysts have given BIOA a Buy based on their latest research and market trends.

According to 8 analysts, BIOA has a Buy consensus rating as of Jun 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioAge Labs Inc (BIOA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.